It looks to us as if Bayer’s management has come to a conclusion for settling the line-up of different plaintiffs across the product portfolio. Compared to the partly settled glyphosate-related claims, those on Essure look a bit less expensive and will not burden the Q3 figures too much. Management is trying to ‘pack’ all the nasty issues into the ‘coronavirus year’.
21 Aug 2020
Another tick on the list
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Another tick on the list
Bayer AG (BAYN:WBO) | 0 0 0.5% | Mkt Cap: 80,975m
- Published:
21 Aug 2020 -
Author:
Martin Schnee -
Pages:
2
It looks to us as if Bayer’s management has come to a conclusion for settling the line-up of different plaintiffs across the product portfolio. Compared to the partly settled glyphosate-related claims, those on Essure look a bit less expensive and will not burden the Q3 figures too much. Management is trying to ‘pack’ all the nasty issues into the ‘coronavirus year’.